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TRABECULAR BONE DENSITY IN 
PREMENOPAUSAL RHEUMATOID 
ARTHRITIS PATIENTS 
A A Kalla, L Bewerunge, A Langley, 0 L Meyers, A B Fataar 
Objective. This study was undertaken to compare trabecular 
bone mineral density (BMD) in premenopausal rheumatoid 
arthritis. (RA) patients and normal age-matched controls. 
Method. A protocol was designed to record age, duration of 
disease, use of corticosteroids (CS) and/ or slow-acting anti-
rheumatic drug (SAARD) therapy together with duration of 
such therapy. BMD was measured using the Hologic QDR 
1 000 dual energy X-ray absorptiometer. The first four 
lumbar vertebrae and the left femur were measured in 56 
RA patients and 165 controls. Height and weight were 
measured. Comparisons were made between RA patients 
and controls, as well as between subgroups of RA patients 
based on CS therapy. 
Results. Patients with RA had significantly lower BMD (P < 
0.05) at all the sites than the normal controls. The mean 
duration of RA at the time of study was 60 months 
(standard deviation 58 months). Thirteen RA patients had 
used CS in doses less than 10 mg daily for 6 months or 
longer (mean 19 months), while 25 patients had been on 
SAARD for an excess of 6 months (mean 23 months). The 
CS-treated patients had significantly lower BMD than 
untreated subjects at the femoral neck and inter-trochanteric 
region (P < 0.05), but not at the lumbar spine. However, 
when compared with normal controls, the CS-treated 
subgroups had significantly lower BMD at the lumbar spine 
and all femoral areas. Trochanteric BMD was the best 
determinant of the RA group, with a sensitivity of 65% and 
specificity of 77%. The positive predictive value was 16%, 
while the negative predictive value was 10%. Using Bayes' 
theorem, the prevalence of osteopenia in RA was found to 
be6%. 
Conclusion. We conclude that generalised bone loss is a 
systemic feature of RA and that loss at the spine and femur 
may be aggravated by CS therapy. 
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Generalised bone loss is a recognised feature of rheumatoid 
arthritis (RA),1·5 but some recent work has failed to show 
significant differences in lumbar bone mineral density (BMD) 
from normal subjects.' Results of earlier studies2·5 are flawed by 
neglect of an extremely important confounding variable in the 
form of the menopause. The state of oestrogen deficiency 
appears to have an overwhelming effect on coupling within the 
bone metabolic unit, as shown by differences in bone gain 
between young ( < 50 years old) and old RA patients receiving 
slow-acting anti-rheumatic drugs (SAARD).7 Oestrogen 
replacement alone has been shown to stabilise BMD in 
postmenopausal RA subjects.8 Guyatt et al.9 have reviewed the 
flaws in several earlier studies, but many recent studies still 
include post-menopausal subjects.10 While it may be possible to 
'normalise' for the menopause, the heterogeneous nature of 
involutional bone loss defies the development of an accurate 
formula to cater for both rapid and slow losers.11 •12 In addition, 
osteoporosis is generally defined by the T-score, which is 
formulated in relation to young normal (premenopausal) 
subjects at peak bone mass. RA may also be associated with 
rapid early bone loss followed by a plateau in loss over time, 
but the confounding effect of the menopause is not known. 
The pathogenesis of bone loss in RA patients is likely to be 
closely linked with the excess osteoclast activators found 
within the pannus.13 Tumour necrosis factor (TNF) and 
interleukin (IL) 1 and 6 are detectable in the serum of RA 
patients, implicating them in localised and generalised bone 
loss in RA. 1" 1' Mast cell products, including kinins, have also 
been implicated.16•17 There is some evidence that SAARD may 
retard bone loss in RA patients.' Recent work has shown a 
relationship between markers of disease activity and early 
trabecular bone loss in RA. 18 BMD and skeletal metabolism 
could potentially be more accurate physiological markers of 
disease modification in RA than erosion counts or joint space 
narrowing scores.''"" 
The effects of low-dose corticosteroid (CS) therapy on bone 
loss in RA are controversial.21 Current opinion suggests that a 
low dose (< 7.5 mg/ day) is unlikely to result in accelerated 
bone loss.22 There is evidence of recovery of BMD after 
stopping CS therapy.10 As several of these studies are based on 
post-menopausal RA patients they are subject to the same 
flaws as studies of non-steroid-treated postmenopausal RA 
patients.' There is an increasing tendency to use CS for 
prolonged periods in RA patients.23-'4 An interesting recent 
report" suggested that in early RA rapid bone loss was greater 
in those patients receiving prednisone < 5 mg daily than in 
those receiving > 5 mg daily, confirming the importance of 
inflammation as a mechanism of bone loss in RA. 
Against this background, a study was designed to evaluate 
trabecular BMD (using dual-energy X-ray absorptiometry 
(DEXA)) in premenopausal, independently mobile RA patients 
and to compare these subjects with young normal controls at 
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peak bone age in order to evaluate the effects of the underlying 
disease, CS and SAARD therapy in the genesis of probable 
differences. 
MATERIAL AND METHODS 
Fifty-six consecutive ambulant female patients under 50 (range 
21 - 48) years of age were studied. They were all regularly 
attending an outpatient arthritis clinic at Groote Schuur 
Hospital (GSH) over a 36-month period. The protocol was 
approved by the Ethics and Research Committee at the 
University of Cape Town (UCT). Age under 50 years, regular 
menstruation, independent ambulation and disease 
classification according to the American College of 
Rheumatology (ACR) revised criteria26 were the main basis for 
selection. Males and pregnant females were excluded. Patients 
were also excluded if they had undergone total hip 
replacement or had any medical condition likely to interfere 
with bone metabolism or BMD measurement, such as epilepsy, 
hyperthyroidism, hyperparathyroidism, amenorrhoea, or 
scoliosis. Our patients clearly represent a highly specific 
population of RA subjects, since confounding variables had to 
be minimised. None of the patients had received calcium 
supplementation before or during the study. There were 41 
coloured, 10 black and 6 white patients in the RA cohort. 
A protocol was designed to record age, race, sex, age at onset 
of disease, duration of disease and criteria for diagnosis of RA. 
The patients had a complete physical examination by a single 
observer (AAK). The use of medication, particularly CS and 
SAARD, was carefully recorded. Functional status was graded 
according to the ACR classification." 
BMD was measured using the Hologic QDR 1 000 
densitometer, using DEXA. The lumbar spine was measured 
from L1 to L4 and the mean lumbar BMD was calculated. The 
left femur was measured at four different sites (neck, 
trochanter, inter-trochanter and Ward's triangle). The total 
femoral BMD was calculated from these values. Radiographs of 
the hips and vertebrae were not done routinely, unless 
specifically indicated by symptoms in those areas. The in vitro 
coefficient of variation (Cv) of the technique at our institution 
was 0.5%, using a phantom measured at regular intervals (N = 
785) during the 3-year period (1990 - 1992). 
One hundred and sixty-five normal female volunteers 
matched for age (range 22 - 48 years) were studied as controls. 
All volunteers used for this study were independently mobile, 
were not on regular medication and had regular menstrual 
cycles. They were not exposed to calcium supplementation at 
any point. There were 110 whites, 51 coloureds and 2 blacks 
among the controls. 
The CS-treated group represents subjects who had been 
receiving continuous therapy for at least 6 months before the 
study and who were currently on treatment. The daily dose 
and duration of CS therapy at the time of study were recorded. 
In general, treated patients received 5 - 10 mg daily. 
Cumulative CS dose was not calculated. Five SAARDs were 
used, namely sodium aurothiomalate, D-penicillamine, 
sulphasalazine, chloroquine and methotrexate. None of our 
patients was receiving or had received calcium supplements or 
vitamin D therapy in the course of the study or at any point in 
the course of the disease. 
STATISTICAL METHODS 
Statistical tests were performed using the STATISTICA package 
on an IBM-compatible personal computer. Analysis of variance 
(ANOVA) was used for univariate comparisons. Multivariate 
discriminant analysis was used to evaluate the sensitivity and 
specificity of the measurement of BMD at the various sites in 
the diagnosis of RA and to predict the CS and SAARD 
subgroups. The independent variables included BMD at the 
lumbar spine and femoral sites. Stepwise multiple regression 
analysis was used to predict lumbar BMD from femoral 
measurements and total femoral or Ward's BMD from lumbar 
and femoral measurements in the controls and total RA group 
as well as the CS and SAARD subgroups, respectively. Age, 
disease duration, height, weight, daily CS dose and duration of 
CS therapy (where appropriate) were included as independent 
variables. 
RESULTS 
The two groups were comparable with regard to age, height 
and weight. The mean lumbar BMD was significantly reduced 
(P = 0.0006) in the RA patients. The BMD was also significantly 
reduced at all the femoral sites in the RA patients (P < 0.01) 
(Table I). Figs 1 and 2 show the differences between RA and 
controls graphically for lumbar spine and total hip BMD, 
respectively, in the form of box and whisker plots. The mean 
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Fig. 1. Box and whisker plots of lumbar bone mineral density 
showing median and 75% interquartile range in patients with 




Table I. Comparison of bone mineral density (g/cm') in patients 
with rheumatoid arthritis (RA) and normal controls matched for 












Total hip 0.957 
(0.1C)) 
Ward's area 0.692 
(0.13) 
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Fig. 2. Box and whisker plots of total femoral bone mineral density 
showing median and 75% interquartile range in patients with 
rheumatoid arthritis (RA) and normal controls. 
Thirteen patients were receiving CS at the time of study. The 
CS-treated and non-CS-treated subgroups of patients were 
comparable for age, height, weight and disease duration. The 
BMD at the femoral neck (P = 0.007) and inter-trochanteric 
region (P = 0.05) were significantly reduced in the CS-treated 
subgroup. The BMD at the lumbar spine, trochanter, Ward's 
area and total hip were not significantly lower in the CS-
treated subgroup (P > 0.20) (Table II). Figs 3 and 4 demonstrate 
the differences between CS-treated and untreated subgroups 
graphically for lumbar spine and total hip BMD, respectively, 
in the form of box and whisker plots. 
When the two subgroups of RA patients were compared 
with the normal controls, the CS-treated subgroup showed 
significantly lower BMD at the lumbar spine and all femoral 
sites (P < 0.01). However, the subgroup not receiving CS 
showed significant differences only at the lumbar spine 
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Table II. Comparison of bone mineral density (g/cm') at various 
sites in rheumatoid arthritis (RA) patients based on current 
therapy with corticosteroids (CS). 
RA patients RA patients 
on CS not on CS 
Variable (SD) (SD) P-value 
Number 13 43 
Age 37 39 NS 
(8) (6) 
DOD 68 56 NS 
(59) (52) 
Lumbar 0.928 1.011 NS 
(0.14) (0.14) 
Femoral Neck 0.724 0.834 0.007 
(0.89) (0.13) 
Trochanter 0.610 0.658 NS 
(0.09) (0.11) 
Inter-trochanter 0.944 1.056 0.05 
(0.14) (0.19) 
Total hip 0.812 0.902 NS 
(0.11) (0.15) 
Ward's area 0.593 0.659 NS 
(0.13) (0.15) 
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Fig. 3. Box and whisker plots of lumbar bone mineral density 
showing median and 75% interquartile range in patients with 
rheumatoid arthritis (RA) receiving corticosteroids (CS) and those 
not currently receiving CS therapy. 
(P = 0.04), trochanter (P = 0.0007), inter-trochanter (P = 0.03) 
and total hip (P = 0.02). At Ward's region, the BMD was not 
significantly lower than normal (Table III). Interestingly, 
patients in the untreated subgroup were significantly shorter (P 
.= 0.009) than the normal controls. The mean duration of CS 
therapy was 19 (SD 14) months, with a mean daily dose of 5 
(SD 5) mg/ day. The cumulative CS dose was not calculated. 
Disease duration did not correlate significantly with BMD at 
any of the sites (not shown). 
Twenty-five patients were receiving SAARD therapy at the 
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Fig. 4. Box and whisker plots of total femoral bone mineral density 
showing median and 75% interquartile range in patients with 
rheumatoid arthritis (RA) receiving corticosteroids (CS) and those 
not currently receiving CS therapy. 
had received the same SAARD for more than 6 months before 
the study (mean 23 months). The treated and untreated 
subgroups were comparable for age and body mass index. 
There were no significant differences between the subgroups 
with regard to BMD at the lumbar spine or the left femur 
(P > 0.20), despite the longer disease duration in the non-
SAARD-treated group. Intention to treat was the method used 
to define SAARD categories. Four patients were receiving 
sodium aurothiomalate, 3 D-penicillamine, 4 chloroquine, 5 
sulphasalazine and 9 methotrexate. Small sample sizes 
precluded inferences from intergroup comparisons. 
Multiple stepwise discriminant analysis was used to 
distinguish between the RA patients and the normal controls. 
The underlying diagnosis was the dependent variable, while 
age, height, weight, total lumbar and femoral regional BMD 
measurements were the independent variables. The 
trochanteric BMD was the best determinant of the RA group, 
with a sensitivity of 65% and specificity of 77%. The positive 
predictive value (PPV) was 16%, while the negative predictive 
value (NPV) was only 10%. Using Bayes' theorem, the 
prevalence of osteopenia at the trochanter was calculated at 
6%. A similar analysis was done to distinguish between CS-
treated and untreated subgroups. Femoral neck BMD was the 
best predictor of the CS-treated subgroup, with a sensitivity of 
81 % and specificity of 82%. The PPV was 31 %, while the NPV 
was 98%. The prevalence of CS-induced osteopenia was 4%. 
None of the BMD measurements featured in the discriminant 
analysis comparing the CS-treated groups with the normal 
controls. The subgroup of RA patients not being treated with 
CS was best distinguished from normal controls by a 
combination of trochanteric and femoral neck BMD. The 
sensitivity was 67% and specificity 80%. The PPV was 5%, 
while the NPV was 99%. In addition, none of the independent 
variables was able to distinguish between the subgroups based 
on SAARD therapy. 
Multiple regression analysis was used to compare the RA 
patients and normal controls in terms of predicting lumbar 
BMD from femoral measurements, age, disease duration, 
height and weight. With regard to lumbar BMD, in the control 
group, trochanteric and total femoral BMD explained the most 
variance in lumbar BMD (r' 47%, P < 0.05), while in the RA 
patients a combination of femoral neck and Ward's BMD 
explained most of the variance in lumbar BMD (r' 59%, P < 0.05). 
When trying to predict total femoral BMD we found that in the 
RA and control group lumbar BMD was not a significant 
predictor and did not feature in the regression equation. 
Table III. Comparison of bone mineral density (g/cm') in patients with rheumatoid arthritis (RA) based on corticosteroid therapy, and normal 
controls matched for age and sex 
RA patients RA patients 
Control on CS not on CS 
Variable (SD) (SD) P-value (SD) P-value 
Number 165 13 43 
Age 37 37 NS 39 NS 
(8) (9) (6) 
Lumbar 1.06 0.928 0.0006 1.011 0.04 
(0.12) (0.14) (0.14) 
Femoral neck 0.859 0.724 0.0003 0.834 0.0004 
(0.13) (0.89) (0.13) 
Trochanter 0.719 0.610 0.0002 0.658 0.0007 
(0.102) (0.09) (0.11) 
Inter-trochanter 1.116 0.944 0.03 1.056 0.()3 
(0.16) (0.14) (0.19) 
Total hip 0.957 0.812 0.0001 0.902 0.02 
(0.13) (0.11) (0.15) 
Ward's area 0.692 0.593 0.01 0.659 NS 
(0.13) (0.13) (0.15) 
SD== standard deviation; NS = not significant. 
Ill 
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The effect of CS on the regression analysis was interesting. In 
predicting lumbar BMD, Ward's BMD was the best predictor in 
the CS-treated patients (r' 56%), as well as the non-treated 
patients (r' 63%). When predicting Ward's BMD, femoral neck 
BMD was the best predictor (r' 94%) in treated patients, while 
a combination of lumbar, total femoral and trochanteric BMD 
was the best predictor (r' 86%) in the non-treated patients. In 
the SAARD subgroup, total femoral BMD was the best 
predictor of lumbar BMD. 
DISCUSSION 
Virtually every non-invasive method of measuring BMD has 
been used in RA patients,1•2•10 yet there are differences of 
opinion regarding generalised bone loss as a feature of the 
disease.28 While researchers have taken cognisance of the 
importance of excluding RA patients in ACR classes III and IV, 
they have assumed that it is possible to 'normalise' for the 
effect of the menopause." Many recent studies still include 
postmenopausal RA patients,10·'0 in spite of the extensive 
criticism of the scientific value of such studies by Guyatt et al.' 
Normalisation for the menopause is not possible when cross-
sectional BMD studies are unable to differentiate between the 
heterogeneity of rapid and slow losers of bone density during 
states of oestrogen deficiency.11·12 We have shown that the 
beneficial effects of SAARD on metacarpal bone density in RA 
are negated after 50 years of age.' A recent study" was unable 
to demonstrate significant differences in DXA measures of 
BMD at the lumbar spine and femur between postmenopausal 
normal controls and age-matched RA patients.'8 The present 
study is one of the few to evaluate a cohort of young 
(premenopausal) RA patients in whom DXA measures have 
been recorded. 
Contrary to the results of earlier reports on postmenopausal 
and perimenopausal RA patients, our data show significant 
osteopenia at the lumbar spine as well as at different sites 
within the femur.6·31 Our patients were all independently mobile 
and many were actively working. It therefore seems unlikely 
that immobilisation could sufficiently explain all the 
differences between the two groups at either site.10 It was 
impossible to match the groups for physical activity and the 
literature is not clear about the minimum exercise required to 
maintain bone density. It is known that the extremes of 
physical activity I inactivity (immobilisation as a result of 
paraplegia, marathon running in males or females) interfere 
with bone metabolism, but it is not known if the sedentary 
la secretarial female seated all day is likely to lose bone mass.32 
Future research should aim at quantifying physical activity in 
order to address the role of this confounding variable in the 
genesis of bone loss, particularly in RA patients. Unfortunately, 
the health assessment questionnaire (HAQ)" and Keitel 
instrument'' measure both disability and disease activity, 
making it difficult to interpret the separate roles of disease 
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activity and disability in the genesis of bone loss in RA using 
such measurements,35·37 Fitness measurement may serve as a 
useful surrogate measure of physical activity.38 The cohort of 
RA patients in our study was not strictly matched for ethnicity 
because of the demographics in the Western Cape. Among 
South Africans, studies have shown that white and coloured 
women (Western Cape)39 and white and black women 
(Gauteng)'0 have comparable BMD at the lumbar and most 
femoral sites. 
The pathogenesis of osteopenia in RA is likely to be related 
to a combination of reduced bone formation and increased 
bone resorption. Kinetic bone studies have, unfortunately, been 
largely confined to postmenopausal subjects, so that the 
contributory roles of age and oestrogen deficiency are not 
clear.38 The pannus is rich in osteoclast activating factors (OAF) 
such as TNF, IL 1 and 6, mast cell products, kinins, 
prostaglandin E (PGE) and osteoclast differentiating factor 
(ODF).13.<1-43 These may spill over into the circulation, resulting 
in localised as well as generalised bone loss in RA. Recent 
work has shown rapid early loss of trabecular bone in patients 
with persistent elevations in C-reactive protein (CRP).18 BMD 
measurement has the potential to be an important marker of 
arrest of the disease with therapy, but confounding variables 
must be minimised.' The pathogenesis of erosions and 
osteoporosis in RA is likely to be due to the same 
mechanisms. 44 
An additional problem in the evaluation of bone loss in RA is 
the differential degree of bone loss at different skeletal sites of 
measurement." This was confirmed by the regression and 
discriminant analyses in this study. Differences are also 
dependent on whether comparisons are made with normal 
controls or subgroups of treated and untreated patients. It is 
possible that different mechanisms, namely physical inactivity 
and inflammation, operate at the different sites.10" 6 Further 
research is needed to study these possibilities. 
The role of low-dose CS in the genesis of bone loss in RA is 
similarly confounded by study of postmenopausal patients.8• 10 
Our findings confirm those of a recent report10 which showed 
that CS have a greater bone-losing effect on the hip than the 
lumbar spine. This pattern has also been shown in non-steroid-
treated RA patients.6 The authors postulate that this may be 
due to disability. Our results (despite the small sample) show 
that the effect of CS is seen at the lumbar spine and left femur, 
contrary to other reports showing a predominant effect on the 
lumbar spine.4•37 The low prevalence of osteoporosis is 
consistent with other reports. 22 The mechanism of CS-induced 
osteoporosis in RA is not fully understood and some workers 
have suggested a protective effect of CS on bone in 
premenopausal RA patients.46 This suggestion would be in line 
with the theoretical possibility that CS have a negative effect on 
TNF, IL, mast cells and PGE. While CS-induced bone loss has 
been shown in male RA patients," it was absent in 
premenopausal systemic lupus erythematosus patients 
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receiving high-dose CS for periods in excess of 6 months)M9 as 
well as different groups of postmenopausal RA patients.6•21 •28 
Clearly, prospective longitudinal observational studies are 
needed to resolve these controversies. Such studies should 
preferably be confined to premenopausal subjects and need to 
compare sites rich in trabecular bone with those rich in cortical 
bone. 
The relationship between disease activity and bone loss in 
RA is interesting.'' Some workers have shown a bone-sparing 
effect of SAARD on bone in RA.50 Our current data do not 
support this effect on trabecular bone. This may be due to the 
fact that our cohort includes patients receiving methotrexate, 
which can potentially cause osteopenia.51 •52 Larger samples need 
to be studied to address this question more carefully. Another 
possible explanation for our apparently contradictory findings 
in SAARD-treated subjects is the cross-sectional nature of our 
study and the small size of the treated subgroups. Longitudinal 
studies may show that SAARD influence the rate of bone loss 
with time. A recent report25 showed surprising longitudinal 
differences in bone loss between RA patients taking CS doses < 
5 mg or > 5 mg daily in early disease.25 
The discriminant analysis showed that the trochanter bears 
the brunt of the uncoupling within the bone metabolic unit in 
RA patients. The prevalence of osteopenia of 6% is lower than 
that reported in studies of cortical bone loss in RA,53 confirming 
that the hands show greater bone loss than other skeletal 
regions.54 The fact that Ward's area and the femoral neck were 
the best predictors of variance in lumbar BMD in our cohort of 
RA patients confirms that trabecular bone is an important 
target of OAFs in RA. Differences in the results of multiple 
regression analysis in the RA and control groups indicate a site-
specific negative effect of RA on trabecular and cortical bone. 
The results of the regression analysis suggest that the effect of 
CS on bone in RA may be an exaggeration of the normal 
processes. It is therefore not surprising that postmenopausal 
RA patients taking CS have a higher incidence of fractures due 
to osteopenia.55 
This study did not address the role of disease activity in the 
pathogenesis of bone loss in RA. We are also unable to 
comment on the relative imbalance between reduced bone 
formation and increased bone resorption in the apparent 
uncoupling. Improved biochemical measures of bone resorption 
such as urinary hydroxy pyridinoline cross-links may be more 
sensitive in RA patients than hydroxy-praline measurement,56 
and this needs to be studied in premenopausal RA females. 
Osteocalcin and alkaline phosphatase are not useful measures 
of bone formation in RA because they are influenced by disease 
activity and CS therapy respectively.57•58 Newer techniques of 
measuring skeletal dynamics may have greater value in RA.1'·20 
Bone biopsy following tetracycline labelling may prove to be 
the most useful method of assessing bone kinetics in RA. These 
would need to be done in patients with early disease who are 
not menopausal. Current evidence from bone biopsy in RA 
suggests that the bone is metabolically inactive in this disease.59 
We conclude that RA causes significant vertebral and femoral 
bone loss in young patients, with a prevalence of osteopenia of 
6%. CS exert their major effect at the femur rather than at the 
lumbar spine, although both sites are affected. There was no 
apparent protective effect from SAARD therapy on trabecular 
bone in this cross-sectional analysis of relatively few patients. 
The pathogenesis and prevention of bone loss in RA needs 
further longitudinal studies in young (premenopausal) patients 
with early disease. 
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NUTRITIONAL STATUS OF RENAL 
TRANSPLANT PATIENTS 
A S du Plessis, H Randall, E Escreet, M Holl, M Conradie, 
M R Moosa, D Labadarios, M G Herselman 
Objective. To assess the effect of renal transplantation on the 
nutritional status of patients. 
Design. Prospective descriptive study. 
Setting. Renal Transplant Clinic at Tygerberg Hospital, 
Western Cape. 
Subjects. Fifty-eight renal transplant patients from Tygerberg 
Hospital were enrolled in the study. The sample was 
divided into two groups of 29 patients each: group 1, less 
than 28 months post-transplant; and group 2, more than 28 
months post-transplant. 
Outcome measures. Nutritional status assessment comprised 
biochemical evaluation, a dietary history, anthropometric 
measurements and a clinical examination. 
Results. Serum vitamin B6 levels were below normal in 56% 
of patients from group 1 and 59% from group 2. Vitamin B6 
intake, however, was insufficient in only 14% of patients 
from group 1and10% from group 2. Serum vitamin C 
levels were below normal in 7% of patients from group 1 
and 24% from group 2, while vitamin C intake was 
insufficient in 21%and14% of patients from groups 1 and 2 
respectively. Serum magnesium levels were below normal 
in 55% of patients from group 1, and in 28% from group 2. 
Serum albumin and cholesterol levels increased 
significantly during the post-transplant period in the total 
sample (P = 0.0001). There was also a significant increase in 
body mass index (P = 0.0001) during the post-transplant 
period. 
Conclusions. Several nutritional abnormalities were 
observed, which primarily reflect the side-effects of 
immunosuppressive therapy. The causes, consequences and 
treatment of the vitamin B6 and vitamin C deficiencies in 
renal transplant recipients need further investigation. 
S Afr Med J 2002; 92: 68-74. 
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